李俭强,杨树森,樊瑛,常惠颖

• 1: 哈尔滨医科大学附属第一医院心内一科
• 2:哈尔滨医科大学附属第一医院心内一科
• 3:哈尔滨医科大学附属第一医院心内一科
• 4:哈尔滨医科大学附属第一医院心内一科

摘要(Abstract)：

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李俭强,杨树森,樊瑛,常惠颖

参考文献(References)：

• [1]Selwyn AP.Prothrombotic and antithrombotic pathways in acute coronary syndromes.Am J Cardiol,2003,91:3H-11H.
• [2]Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin-resistant throm-boxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105:1650-1655.
• [3]Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris sched-uled for elective coronary stent placement.Thromb Haemost,2003,89:783-787.
• [4]Soffer D,Moussa I,Harjai KJ,et al.Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more ag-gressive dosing regimens in unstable angina?Catheter Cardiovasc Interv,2003,59:21-25.
• [5]Aleil B,Ravanat C,Cazenave JP,et al.Flow cytometric analy-sis of intraplatelet VASP phosphorylation for the detection of clo-pidogrel resistance in patients with ischemic cardiovascular disea-ses.J Thromb Haemost,2005,3:85-92.
• [6]Serebruany VL,Steinhubl SR,Berger PB,et al.Variability in platelet responsiveness to clopidogrel among544individuals.J Am Coll Cardiol,2005,45:246-251.
• [7]Woulfe D,Yang J,Brass L.ADP and platelets:the end of the beginning.J Clin Invest,2001,107:1503-1505.
• [8]Kunapuli SP,Dorsam RT,Kim S,et al.Platelet purinergic re-ceptors.Curr Opin Pharmacol,2003,3:175-180.
• [9]Conley PB,Delaney SM.Scientific and therapeutic insights into the role of the platelet P2Y12receptor in thrombosis.Curr Opin Hematol,2003,10:333-338.
• [10]Ding Z,Kim S,Dorsam RT,et al.Inactivation of the human P2Y12receptor by thiol reagents requires interaction with both extracellular cysteine residues,Cys17and Cys270.Blood,2003,101:3908-3914.
• [11]Savcic M,Hauert J,Bachmann F,et al.Clopidogrel loading dose regimens:kinetic profile of pharmacodynamic response in healthy subjects.Semin Thromb Hemost,1999,25(Suppl2):15-19.
• [12]Gilles M,Georges S,Catherine M,et al.A Randomized Com-parison of High Clopidogrel Loading Doses in Patients With Non ST-Segment Elevation Acute Coronary Syndromes:The ALBION(Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation,Inflammation and Ongoing Necrosis)Trial.J Am Coll Cardiol,2006,48:931-938.
• [13]Quinn MJ,Bhatt DL,Zidar F,et al.Effect of clopidogrel pre-treatment on inflammatory marker expression in patients undergo-ing percutaneous coronary intervention.AmJ Cardiol,2004,93:679-684.
• [14]Vivekananthan DP,Bhatt DL,Chew DP,et al.Effect of clopi-dogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.Am J Cardiol,2004,94:358-360.
• [15]Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting:Response varisbility,drug resistance,and the effect of pretreatment platelet reactivity.Circulation,2003,107:2908-2913.
• [16]Barragan P,Bouvier JL,Roquebert PO,et al.Resistance to thienopyridines:clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphoryla-tion.Catheter Cardiovasc Interv,2003,59:295-302.
• [17]Gurbel PA,Bliden KP,Samara W,et al.Clopidogrel effect on platelet reactivity in patients with stent thrombosis:results of the CRESTStudy.Am J Cardiol,2005,46,1827-1832.
• [18]Gurbel PA,Bliden KP,Guyer K,et al.Platelet reactivity in pa-tients and recurrent events post-stenting:results of the PREPARE POST-STENTING Study.Am J Cardiol,2005,46:1820-1826.
• [19]Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel resist-ance is associated with increased risk of recurrent atherothrombot-ic events in patients with acute myocardial infarction.Circula-tion,2004,109:3171-3175.
• [20]Lau WC,Waskell LA,Watkins PB,et al.Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction.Circulation,2003,107:32-37.
• [21]Neubauer H,Gunesdogan B,Hanefeld C,et al.Lipophilic st-atins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study.Eur Heart J,2003,24:1744-1749.
• [22]Saw J,Steinhubl SR,Berger PB,et al.Lack of adverse clopi-dogrel-atorvastatin clinical interaction fromsecondary analysis of a randomized,placebo-controlled clopidogrel trial.Circulation,2003,108:921-924.
• [23]Wienbergen H,Gitt AK,Schiele R,et al.Comparison of clini-cal benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.Am J Cardiol,2003,92:285-288.
• [24]Serebruany VL,Midei MG,Malinin AI,et al.Absence of inter-action between atorvastatin or other statins and clopidogrel:re-sults from the interaction study.Arch Intern Med,2004,164:2051-2057.
• [25]Fontana P,Dupont A,Gandrille S,et al.Adenosine diphos-phate-induced platelet aggregation is associated with P2Y12gene sequence variations in healthy subjects.Circulation,2003,108:989-995.
• [26]Fontana P,Gaussem P,Aiach M,et al.P2Y12H2haplotype is associated with peripheral arterial disease:a case-control study.Circulation,2003,108:2971-2973.
• [27]Lau WC,Gurbel PA,Watkins PB,et al.Contribution of hepatic cytochrome P4503A4metabolic activity to the phenomenon of clopidogrel resistance.Circulation,2004,109:166-171.
• [28]Hechler B,Zhang Y,Eckly A,et al.Lineage-specific overex-pression of the P2Y1receptor induces platelet hyper-reactivity in transgenic mice.J Thromb Haemost,2003,1:155-163.
• [29]Angiolillo DJ,Bernardo E,Ramirez C,et al.Insulin therapy is associated with platelet dysfunction in patients with type2diabe-tes mellitus on dual oral antiplatelet treatment.Am J Cardiol,2006,48:298-304.
• [30]Dziewierz A,Dudek D,Heba G,et al.Inter-individual variabili-ty in response to clopidogrel in patients with coronary artery dis-ease.Kardiol Pol,2005,62:108-117.
• [31]Muller I,Seyfarth M,Rudiger S,et al.Effect of a high loading dose of clopidogrel on platelet function in patients undergoing cor-onary stent placement.Heart,2001,85:92-93.
• [32]Silber S,Albertsson P,Aviles FF,et al.Guidelines for percuta-neous coronary interventions.The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.Eur Heart J,2005,26:804-847.
• [33]Smith SC Jr.ACC/AHA/SCAI2005guideline update for percu-taneous coronary intervention-summary article:a report of Ameri-can Collage of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/SCAI Writing Committee to update the2001Guidelines for Percutaneous Coronary Interven-tion).Circulation,2006,113:156-175.
• [34]Wiviott SD.JUMBO-TIMI26Investigators(2005)Randomized comparison of prasugrel(CS-747,LY640315),a novel thienopy-ridine P2Y12antagonist,with clopidogrel in percutaneous coro-nary intervention:results of the Joint Utilization of Medications to Block Platelets Optimally(JUMBO)-TIMI26trial.Circulation,2005,111:3366-3373.